Biotech Blueprint

Novo's CagriSema Loses to Zepbound, Grail Stumbles, FDA Hardens Its Stance – This Week in Biotech #91

Novo Nordisk’s CagriSema combination missed the primary non‑inferiority endpoint against Eli Lilly’s tirzepatide (Zepbound) in the 84‑week REDEFINE 4 obesity trial, posting 23.0% versus 25.5% weight loss. At the same time, Grail’s large NHS‑Galleri screening study failed to achieve its primary reduction in stage 3‑4 cancers, dampening hopes for population‑wide blood‑based cancer detection. The FDA commissioner also warned investors that invasive rare‑disease delivery methods, such as intracerebral gene vectors, will face tighter scrutiny, sending uniQure’s stock down roughly 30%.